Name | Value |
---|---|
Revenues | 19.1M |
Cost of Revenue | 17.5M |
Gross Profit | 1.5M |
Operating Expense | 63.6M |
Operating I/L | 41.2M |
Other Income/Expense | -47.5M |
Interest Income | 97.3M |
Pretax | -6.3M |
Income Tax Expense | 2.3M |
Net Income/Loss | -8.6M |
Alvotech Holdings SA and its subsidiaries specialize in the development and manufacturing of biosimilars for global markets. By creating high-quality and cost-effective alternatives to existing biologic drugs, the company aims to address the growing demand for affordable biopharmaceuticals. With a focus on biosimilar products, Alvotech generates revenue through the sale and distribution of these pharmaceuticals to healthcare providers, pharmacies, and other stakeholders in the global market.